Proposal for the standardization of flow cytometry protocols to detect minimal residual disease in acute lymphoblastic leukemia

Detalhes bibliográficos
Autor(a) principal: Ikoma,Maura Rosane Valério
Data de Publicação: 2015
Outros Autores: Beltrame,Miriam Perlingeiro, Ferreira,Silvia Inês Alejandra Cordoba Pires, Souto,Elizabeth Xisto, Malvezzi,Mariester, Yamamoto,Mihoko
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Revista brasileira de hematologia e hemoterapia (Online)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842015000600406
Resumo: ABSTRACT Minimal residual disease is the most powerful predictor of outcome in acute leukemia and is useful in therapeutic stratification for acute lymphoblastic leukemia protocols. Nowadays, the most reliable methods for studying minimal residual disease in acute lymphoblastic leukemia are multiparametric flow cytometry and polymerase chain reaction. Both provide similar results at a minimal residual disease level of 0.01% of normal cells, that is, detection of one leukemic cell in up to 10,000 normal nucleated cells. Currently, therapeutic protocols establish the minimal residual disease threshold value at the most informative time points according to the appropriate methodology employed. The expertise of the laboratory in a cancer center or a cooperative group could be the most important factor in determining which method should be used. In Brazil, multiparametric flow cytometry laboratories are available in most leukemia treatment centers, but multiparametric flow cytometry processes must be standardized for minimal residual disease investigations in order to offer reliable and reproducible results that ensure quality in the clinical application of the method. The Minimal Residual Disease Working Group of the Brazilian Society of Bone Marrow Transplantation (SBTMO) was created with that aim. This paper presents recommendations for the detection of minimal residual disease in acute lymphoblastic leukemia based on the literature and expertise of the laboratories who participated in this consensus, including pre-analytical and analytical methods. This paper also recommends that both multiparametric flow cytometry and polymerase chain reaction are complementary methods, and so more laboratories with expertise in immunoglobulin/T cell receptor (Ig/TCR) gene assays are necessary in Brazil.
id ABHHTC-1_02ee157d83f5ac7a8ebc24e925bed8ab
oai_identifier_str oai:scielo:S1516-84842015000600406
network_acronym_str ABHHTC-1
network_name_str Revista brasileira de hematologia e hemoterapia (Online)
repository_id_str
spelling Proposal for the standardization of flow cytometry protocols to detect minimal residual disease in acute lymphoblastic leukemiaMinimal residual diseaseMRD acute lymphoblastic leukemiaFlow cytometryImmunophenotypingABSTRACT Minimal residual disease is the most powerful predictor of outcome in acute leukemia and is useful in therapeutic stratification for acute lymphoblastic leukemia protocols. Nowadays, the most reliable methods for studying minimal residual disease in acute lymphoblastic leukemia are multiparametric flow cytometry and polymerase chain reaction. Both provide similar results at a minimal residual disease level of 0.01% of normal cells, that is, detection of one leukemic cell in up to 10,000 normal nucleated cells. Currently, therapeutic protocols establish the minimal residual disease threshold value at the most informative time points according to the appropriate methodology employed. The expertise of the laboratory in a cancer center or a cooperative group could be the most important factor in determining which method should be used. In Brazil, multiparametric flow cytometry laboratories are available in most leukemia treatment centers, but multiparametric flow cytometry processes must be standardized for minimal residual disease investigations in order to offer reliable and reproducible results that ensure quality in the clinical application of the method. The Minimal Residual Disease Working Group of the Brazilian Society of Bone Marrow Transplantation (SBTMO) was created with that aim. This paper presents recommendations for the detection of minimal residual disease in acute lymphoblastic leukemia based on the literature and expertise of the laboratories who participated in this consensus, including pre-analytical and analytical methods. This paper also recommends that both multiparametric flow cytometry and polymerase chain reaction are complementary methods, and so more laboratories with expertise in immunoglobulin/T cell receptor (Ig/TCR) gene assays are necessary in Brazil.Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular2015-12-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842015000600406Revista Brasileira de Hematologia e Hemoterapia v.37 n.6 2015reponame:Revista brasileira de hematologia e hemoterapia (Online)instname:Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular (ABHHTC)instacron:ABHHTC10.1016/j.bjhh.2015.07.012info:eu-repo/semantics/openAccessIkoma,Maura Rosane ValérioBeltrame,Miriam PerlingeiroFerreira,Silvia Inês Alejandra Cordoba PiresSouto,Elizabeth XistoMalvezzi,MariesterYamamoto,Mihokoeng2016-01-07T00:00:00Zoai:scielo:S1516-84842015000600406Revistahttp://www.rbhh.org/pt/archivo/https://old.scielo.br/oai/scielo-oai.phpsbhh@terra.com.br||secretaria@rbhh.org1806-08701516-8484opendoar:2016-01-07T00:00Revista brasileira de hematologia e hemoterapia (Online) - Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular (ABHHTC)false
dc.title.none.fl_str_mv Proposal for the standardization of flow cytometry protocols to detect minimal residual disease in acute lymphoblastic leukemia
title Proposal for the standardization of flow cytometry protocols to detect minimal residual disease in acute lymphoblastic leukemia
spellingShingle Proposal for the standardization of flow cytometry protocols to detect minimal residual disease in acute lymphoblastic leukemia
Ikoma,Maura Rosane Valério
Minimal residual disease
MRD acute lymphoblastic leukemia
Flow cytometry
Immunophenotyping
title_short Proposal for the standardization of flow cytometry protocols to detect minimal residual disease in acute lymphoblastic leukemia
title_full Proposal for the standardization of flow cytometry protocols to detect minimal residual disease in acute lymphoblastic leukemia
title_fullStr Proposal for the standardization of flow cytometry protocols to detect minimal residual disease in acute lymphoblastic leukemia
title_full_unstemmed Proposal for the standardization of flow cytometry protocols to detect minimal residual disease in acute lymphoblastic leukemia
title_sort Proposal for the standardization of flow cytometry protocols to detect minimal residual disease in acute lymphoblastic leukemia
author Ikoma,Maura Rosane Valério
author_facet Ikoma,Maura Rosane Valério
Beltrame,Miriam Perlingeiro
Ferreira,Silvia Inês Alejandra Cordoba Pires
Souto,Elizabeth Xisto
Malvezzi,Mariester
Yamamoto,Mihoko
author_role author
author2 Beltrame,Miriam Perlingeiro
Ferreira,Silvia Inês Alejandra Cordoba Pires
Souto,Elizabeth Xisto
Malvezzi,Mariester
Yamamoto,Mihoko
author2_role author
author
author
author
author
dc.contributor.author.fl_str_mv Ikoma,Maura Rosane Valério
Beltrame,Miriam Perlingeiro
Ferreira,Silvia Inês Alejandra Cordoba Pires
Souto,Elizabeth Xisto
Malvezzi,Mariester
Yamamoto,Mihoko
dc.subject.por.fl_str_mv Minimal residual disease
MRD acute lymphoblastic leukemia
Flow cytometry
Immunophenotyping
topic Minimal residual disease
MRD acute lymphoblastic leukemia
Flow cytometry
Immunophenotyping
description ABSTRACT Minimal residual disease is the most powerful predictor of outcome in acute leukemia and is useful in therapeutic stratification for acute lymphoblastic leukemia protocols. Nowadays, the most reliable methods for studying minimal residual disease in acute lymphoblastic leukemia are multiparametric flow cytometry and polymerase chain reaction. Both provide similar results at a minimal residual disease level of 0.01% of normal cells, that is, detection of one leukemic cell in up to 10,000 normal nucleated cells. Currently, therapeutic protocols establish the minimal residual disease threshold value at the most informative time points according to the appropriate methodology employed. The expertise of the laboratory in a cancer center or a cooperative group could be the most important factor in determining which method should be used. In Brazil, multiparametric flow cytometry laboratories are available in most leukemia treatment centers, but multiparametric flow cytometry processes must be standardized for minimal residual disease investigations in order to offer reliable and reproducible results that ensure quality in the clinical application of the method. The Minimal Residual Disease Working Group of the Brazilian Society of Bone Marrow Transplantation (SBTMO) was created with that aim. This paper presents recommendations for the detection of minimal residual disease in acute lymphoblastic leukemia based on the literature and expertise of the laboratories who participated in this consensus, including pre-analytical and analytical methods. This paper also recommends that both multiparametric flow cytometry and polymerase chain reaction are complementary methods, and so more laboratories with expertise in immunoglobulin/T cell receptor (Ig/TCR) gene assays are necessary in Brazil.
publishDate 2015
dc.date.none.fl_str_mv 2015-12-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842015000600406
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1516-84842015000600406
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1016/j.bjhh.2015.07.012
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular
publisher.none.fl_str_mv Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular
dc.source.none.fl_str_mv Revista Brasileira de Hematologia e Hemoterapia v.37 n.6 2015
reponame:Revista brasileira de hematologia e hemoterapia (Online)
instname:Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular (ABHHTC)
instacron:ABHHTC
instname_str Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular (ABHHTC)
instacron_str ABHHTC
institution ABHHTC
reponame_str Revista brasileira de hematologia e hemoterapia (Online)
collection Revista brasileira de hematologia e hemoterapia (Online)
repository.name.fl_str_mv Revista brasileira de hematologia e hemoterapia (Online) - Associação Brasileira de Hematologia e Hemoterapia e Terapia Celular (ABHHTC)
repository.mail.fl_str_mv sbhh@terra.com.br||secretaria@rbhh.org
_version_ 1754213112779636736